Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the United States and Canada. The company is headquartered in Morrisville, North Carolina.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.49M |
| Operating Margin | 0.00% |
| Return on Equity | -59.80% |
| Return on Assets | -37.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.29 |
| Price-to-Book | 0.60 |
| Price-to-Sales (TTM) | 414.72 |
| EV/Revenue | 263.34 |
| EV/EBITDA | -0.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $37.42M |
| Float | $29.86M |
| % Insiders | 0.18% |
| % Institutions | 114.95% |
Volatility is currently expanding
LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law.
Lawsuit alleges Tenax Therapeutics, Inc. made misleading statements to investors from November 13, 2023 to August 7, 2026; lead plaintiff motions are due December 28, 2026 LOS ANGELES, Nov. 6, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who acquired the Company's securities from November 13, 2023 to August 7, 2026.
Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
New York, New York--(Newsfile Corp. - November 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Tenax and have suffered losses, you may CLICK HERE to contact us.
Notice to Pension Funds, Asset Managers, and Fiduciaries: the lawsuit alleges Tenax overstated TNX-103's clinical prospects while raising $134 million, largely through private placements, before its Phase 3 LEVEL trial missed its primary endpoint. NEW YORK, Nov. 5, 2026 /PRNewswire/ -- SueWallSt notifies institutional investors, ERISA plan fiduciaries, and asset managers that a class action lawsuit has been filed on behalf of purchasers of Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 5, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and reminds investors of the December 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress.
LOS ANGELES--(BUSINESS WIRE)--The deadline for Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) investors to seek appointment as lead plaintiff in a securities class action lawsuit is December 28, 2026. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities from November 13, 2023 to August 7, 2026, inclusive. The Law Offices of Frank R. Cruz today reminded investors of the deadline in the case, Katz v. Tenax Therapeu.
Philadelphia, Pennsylvania--(Newsfile Corp. - November 4, 2026) - Berger Montague, a leading national plaintiffs' law firm, announces a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) ("Tenax" or the "Company") on behalf of investors who purchased or otherwise acquired Tenax securities during the period from November 13, 2023 through August 7, 2026 (the "Class Period"). The deadline to apply for lead plaintiff is December 28, 2026.
Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TENX and any ticker you trade — then tracks every position and per-strategy win rate.
